Comparing Depo-Provera vs Larin Fe 1/20
| Depo-Provera | Larin Fe 1/20 |
|
|---|
| Depo-Provera (medroxyprogesterone) | Larin Fe 1/20 (ethinyl estradiol / norethindrone) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Birth Control. Depo-Provera may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Birth Control. Larin Fe 1/20 may also be used for purposes not listed in this medication guide. |
Related suggestions Birth Control (Contraception)
|
|||||||||||||||
| More about Depo-Provera (medroxyprogesterone) | More about Larin Fe 1/20 (ethinyl estradiol / norethindrone) | ||||||||||||||||
| Generic Status | |||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Depo-Provera has an average rating of 4.2 out of 10 from a total of 1969 ratings on Drugs.com. 28% of reviewers reported a positive effect, while 55% reported a negative effect. |
Larin Fe 1/20 has an average rating of 4.2 out of 10 from a total of 128 ratings on Drugs.com. 24% of reviewers reported a positive effect, while 54% reported a negative effect. |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Side Effects | |||||||||||||||||
|
See also: Depo-Provera side effects in more detail. |
See also: Larin Fe 1/20 side effects in more detail. |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Depo-Provera prices and generic prices |
View all Larin Fe 1/20 prices and generic prices |
||||||||||||||||
| Dosage Form(s) Available | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Other medroxyprogesterone brands include: depo-subQ provera 104, Provera | Other ethinyl estradiol / norethindrone brands include: Alyacen 1/35, Alyacen 7/7/7, Aranelle, Aurovela 1.5/30, Aurovela 1/20, Aurovela 24 Fe, Aurovela Fe 1.5/30, Aurovela Fe 1/20, Balziva, Blisovi 24 Fe, Blisovi Fe 1.5/30, Blisovi Fe 1/20, Brevicon, Briellyn, Chabelina Fe, Charlotte 24 Fe, Cyclafem 0.5/35, Cyclafem 1/35, Cyclafem 7/7/7, Cyonanz, Dasetta, Dasetta 1/35, Dasetta 7/7/7, Estrostep Fe, Femcon Fe, femhrt, Finzala, Fyavolv, Gemmily, Generess Fe, Gildagia, Gildess 1.5/30, Gildess 1/20, Gildess 24 Fe, Gildess Fe 1.5/30, Gildess Fe 1/20, Hailey 1.5/30, Hailey 24 Fe, Hailey Fe 1.5/30, Hailey Fe 1/20, Jinteli, Junel 1.5/30, Junel 1/20, Junel Fe 1.5/30, Junel Fe 1/20, Junel Fe 24, Kaitlib Fe, Larin 1.5/30, Larin 1/20, Larin 24 Fe, Larin Fe 1.5/30, Layolis Fe, Leena, Leribane, Lo Loestrin Fe, Loestrin 21 1/20, Lomedia 24 Fe, Melodetta 24 Fe, Merzee, Mibelas 24 Fe, Microgestin 1.5/30, Microgestin 1/20, Microgestin Fe 1.5/30, Microgestin Fe 1/20, Minastrin 24 Fe, Necon 0.5/35, Necon 7/7/7, Nexesta Fe, Norinyl 1+35, Nortrel 0.5/35, Nortrel 1/35, Nortrel 7/7/7, Nylia 1/35, Nylia 7/7/7, Ortho-Novum 7/7/7, Philith, Pirmella 1/35, Pirmella 7/7/7, Rhuzdah, Tarina 24 Fe, Tarina Fe 1/20, Taysofy, Taytulla, Tilia Fe, Tri-Legest, Tri-Legest Fe, Vyfemla, Wera, Wymzya Fe, Zenchent, Zenchent Fe View more | ||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | |||||||||||||||||
|
401 hours |
14 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 229 drugs are known to interact with Depo-Provera:
|
A total of 450 drugs are known to interact with Larin Fe 1/20:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
|
|||||||||||||||||
| First Approval Date | |||||||||||||||||
|
September 23, 1960 |
N/A |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.